Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT440 in adolescents and adults with sickle cell disease (Phase 3)
2016-003370-40Phase 3Completed
- Sponsor
- Global Blood Therapeutics, Inc.
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics, Inc.. Started Dec 2016; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2016-003370-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003370-40.